Nanoemulsion-based Vaccine to Combat a Wide Variety of Antigens

NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with "Innate Immune Receptors and Adjuvant Discovery." NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan. NanoBio will receive a subcontract of approximately $4.1 million over the research period to support efforts aimed at developing nanoemulsion-based mucosal vaccine adjuvants for a wide variety of antigens.

"NanoBio's nanoemulsion-based vaccine adjuvant platform has consistently demonstrated the ability to elicit robust systemic, cellular and mucosal immunity, based on studies we've conducted in numerous diseases using various antigen types," commented David Peralta, NanoBio's CFO and COO. "This award will fund extensive additional research that will allow NanoBio and the University of Michigan to further advance our adjuvant platform for vaccines."

NanoBio announced earlier in 2009 that the U.S. Food and Drug Administration (FDA) approved the company's Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper. The Phase 1 study is currently ongoing.

The underlying technology is NanoBio's NanoStat platform, which employs a nanoemulsion that is created through a proprietary manufacturing process. The nanoemulsion is uniquely capable of permeating the nasal mucosa, where it can load vaccine antigen into immune-presenting cells. These cells then carry the antigen to areas of the body that initiate an immune response, including the lymph nodes, thymus and spleen.

"Our unique approach to inducing immunity leverages nasal immune elements to produce a level of protective immunity not seen with currently available vaccines," added Mr. Peralta. "This funding will enable NanoBio to make tremendous advances in terms of mucosal vaccination, which could provide significant advantages with respect to disease protection worldwide."

NanoBio's nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases. The company's NanoStat adjuvant platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles.

NanoBio Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat technology platform. The company's lead dermatology and anti-infective product candidates include treatments for herpes labialis (cold sores), onychomycosis (nail fungus), tinea capitis, acne, molluscum contagiosum, and cystic fibrosis. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan. NanoBio is a spin-off from the University of Michigan and holds the exclusive global license to the nanoemulsion platform technology.

Posted on October 14th, 2009

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoBio Corp.. (2019, March 18). Nanoemulsion-based Vaccine to Combat a Wide Variety of Antigens. AZoNano. Retrieved on February 23, 2024 from https://www.azonano.com/news.aspx?newsID=14142.

  • MLA

    NanoBio Corp.. "Nanoemulsion-based Vaccine to Combat a Wide Variety of Antigens". AZoNano. 23 February 2024. <https://www.azonano.com/news.aspx?newsID=14142>.

  • Chicago

    NanoBio Corp.. "Nanoemulsion-based Vaccine to Combat a Wide Variety of Antigens". AZoNano. https://www.azonano.com/news.aspx?newsID=14142. (accessed February 23, 2024).

  • Harvard

    NanoBio Corp.. 2019. Nanoemulsion-based Vaccine to Combat a Wide Variety of Antigens. AZoNano, viewed 23 February 2024, https://www.azonano.com/news.aspx?newsID=14142.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.